Lundbeck Dodges FTC Suit Over Heart Drugs

Law360, New York (September 9, 2010, 5:57 PM EDT) -- A federal judge has ruled that Lundbeck Inc., the U.S. arm of Danish drugmaker H. Lundbeck A/S, did not violate antitrust laws when it cornered the market on drugs used to treat congenital heart defects in premature babies.

After hearing testimony from physicians and economists, Judge Joan N. Erickson of the U.S. District Court for the District of Minnesota ruled that the Federal Trade Commission did not sufficiently make the case that the drugs, NeoProfen and Indocin IV, were in the same product market.

The judge...
To view the full article, register now.